ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

Von Eschenbach says oncology is undergoing a “revolutionary evolution.”

May 20, 2005

Bristol-Myers Squibb Board Removes CEO Peter Dolan Over Plavix Deal. Two Republican Senators Say They Will Place Holds On Confirmation of Andrew von Eschenbach as FDA Commissioner. Craig Thompson Named Director of Abramson Cancer Center.

September 15, 2006

Rauscher Decision Put Off To July 1: Administration Backs Pay Raise Bill

June 25, 1976

FDA Oncologic Drugs Advisory Committee Okays THC For Group C List

July 4, 1980

Rosenberg Team May Have Cloned Melanoma Gene

May 31, 1991

Also in this 8-page issue: Senate Labor-HHS finds an extra $1 billion for NIH; Appropriations Committee reports bill to Senate.

July 15, 2005